2.72

1.09% -0.03

After Hours: 2.72

Protalix BioTherapeutics Inc. (PLX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Protalix BioTherapeutics Inc. stock is traded at $2.72, with a volume of 386.02K. It is down -1.09% in the last 24 hours and up +13.33% over the past month. Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.

Previous Close:

$2.75

Open:

$2.76

24h Volume:

386.02K

Relative Volume:

0.55

Market Cap:

$219.15M

Revenue:

$52.74M

Net Income/Loss:

$-6.60M

P/E Ratio:

-32.19

EPS:

-0.0845

Net Cash Flow:

$-13.63M

1W Performance:

+1.12%

1M Performance:

+13.33%

6M Performance:

+25.93%

1Y Performance:

+33.33%

1-Day Range:

$2.70

$2.775

1-Week Range:

$2.69

$2.8495

52-Week Range:

$1.60

$3.19

Protalix BioTherapeutics Inc. Stock (PLX) Company Profile

Name

Protalix BioTherapeutics Inc.

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

972 4 988 9488

Address

2 Snunit Street, Science Park PO Box 455, Karmiel

Employee

190

Twitter

@Protalix_Bio

Next Earnings Date

2026-11-12

Latest SEC Filings

PLX's Discussions on Twitter

Compare PLX vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PLX Protalix BioTherapeutics Inc.	2.72	219.15M	52.74M	-6.60M	-13.63M	-0.0845
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-08-20	Reiterated	H.C. Wainwright	Buy
Apr-17-17	Reiterated	Rodman & Renshaw	Buy
Apr-04-16	Initiated	Rodman & Renshaw	Buy
Apr-23-15	Upgrade	Jefferies	Hold → Buy
Nov-12-14	Reiterated	R. F. Lafferty	Buy
Jan-24-14	Initiated	R. F. Lafferty	Buy
May-02-12	Downgrade	Canaccord Genuity	Buy → Hold
May-02-12	Reiterated	Oppenheimer	Outperform
Apr-30-12	Downgrade	Auriga	Buy → Hold
Oct-13-11	Initiated	Morgan Joseph	Hold
Mar-17-11	Downgrade	WBB Securities	Strong Buy → Buy
Nov-09-10	Reiterated	Oppenheimer	Outperform
Oct-14-10	Reiterated	UBS	Buy
Dec-02-09	Reiterated	Hapoalim	Outperform
Sep-22-09	Initiated	Canaccord Adams	Buy
Sep-02-09	Initiated	Hapoalim	Outperform
Dec-01-08	Reiterated	Oppenheimer	Outperform
Mar-11-08	Initiated	UBS	Buy
Nov-20-07	Initiated	CIBC Wrld Mkts	Sector Outperform

View All

Protalix BioTherapeutics Inc. Stock (PLX) Latest News

Sep 16, 2026

Protalix at Morgan Stanley conference: rare-disease growth in focus By Investing.com - Investing.com Canada

Sep 16, 2026

Sep 09, 2026

Director at Protalix (NYSE: PLX) gets options expiring 2036 plus 8,500 RSUs - Stock Titan

Sep 09, 2026

PLX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus

Sep 09, 2026

Sep 08, 2026

Protalix BioTherapeutics Grants 168,000 Derivative Securities to Executive Naos Yaron (AMEX: PLX) - Kalkine Media

Sep 08, 2026

Protalix BioTherapeutics (AMEX: PLX) Grants 25,500 Derivative Securities to Insider Forster Eliot - Kalkine Media

Sep 08, 2026

Protalix (NYSE: PLX) sets CEO equity to 3-year vesting, change-in-control terms - stocktitan.net

Sep 04, 2026

Yaron Naos awarded new equity at Protalix BioTherapeutics (PLX) - Stock Titan

Sep 04, 2026

Director at Protalix BioTherapeutics (PLX) gets new options and stock units - Stock Titan

Sep 04, 2026

Protalix (PLX) awards Amos Bar‑Shalev new 3‑year equity grant - Stock Titan

Sep 04, 2026

Board member at Protalix (PLX) gets new stock and option grant - Stock Titan

Sep 04, 2026

Aug 20, 2026

Zacks Research Issues Pessimistic Outlook for PLX Earnings - MarketBeat

Aug 20, 2026

Aug 19, 2026

Protalix (PLX) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 19, 2026

Protalix (PLX) Q2 2026 Earnings Call Transcript - The Motley Fool

Aug 19, 2026

Aug 18, 2026

Protalix (PLX) Q2 2026 Filing Snapshot: EPS Clears the Reported Estimate in the Current Update; Share-Price Check - dars.gov.et

Aug 18, 2026

Aug 16, 2026

Protalix BioTherapeutics (NYSEAMERICAN:PLX) Advances Plant-Cell Protein Programs - Kalkine Media

Aug 16, 2026

Aug 13, 2026

Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 13, 2026

PLX: Elfabrio Estimates Up - Yahoo Finance

Aug 13, 2026

Aug 12, 2026